William Blair Reaffirms Outperform Rating for argenx (NASDAQ:ARGX)

William Blair reaffirmed their outperform rating on shares of argenx (NASDAQ:ARGX) in a research report released on Friday,RTT News reports.

A number of other research analysts also recently commented on ARGX. Baird R W downgraded shares of argenx from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 1st. JMP Securities lifted their price objective on shares of argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a research report on Tuesday, January 14th. HC Wainwright lifted their price objective on shares of argenx from $717.00 to $720.00 and gave the company a “buy” rating in a research report on Friday. Wolfe Research raised shares of argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 price objective for the company in a research report on Tuesday, November 12th. Finally, Wedbush reissued an “outperform” rating and issued a $655.00 price objective on shares of argenx in a research report on Tuesday, December 3rd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, argenx presently has a consensus rating of “Moderate Buy” and an average price target of $661.17.

argenx Trading Down 0.0 %

argenx stock opened at $624.67 on Friday. The company has a market cap of $37.96 billion, a P/E ratio of -709.85 and a beta of 0.58. argenx has a 1-year low of $349.86 and a 1-year high of $678.21. The company has a fifty day simple moving average of $642.61 and a 200 day simple moving average of $589.72.

argenx (NASDAQ:ARGX) last released its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $0.98 by $0.60. The business had revenue of $761.22 million during the quarter, compared to the consensus estimate of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. On average, equities research analysts forecast that argenx will post 3.13 EPS for the current year.

Institutional Trading of argenx

Several hedge funds and other institutional investors have recently bought and sold shares of ARGX. GeoWealth Management LLC increased its holdings in argenx by 56.3% in the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock valued at $31,000 after buying an additional 18 shares during the period. Whipplewood Advisors LLC bought a new position in argenx in the 4th quarter valued at about $37,000. Global Retirement Partners LLC increased its holdings in argenx by 369.2% in the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock valued at $38,000 after buying an additional 48 shares during the period. FIL Ltd bought a new position in argenx in the 4th quarter valued at about $38,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in argenx in the 4th quarter valued at about $38,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.